All eyes are on Align Technology as the company prepares to release its fourth-quarter financial results after today’s market close. This key report arrives amidst a strategic push into academic research, with the company’s latest collaboration in Switzerland highlighting its long-term vision.
Earnings Expectations Under the Microscope
The primary focus for the market is the forthcoming Q4 2025 earnings release. Consensus estimates project revenue of approximately $1.03 billion. Adjusted earnings per share (EPS) are anticipated to come in around $2.99. These figures will serve as a critical barometer for the strength of consumer demand during the crucial year-end period.
Shifting Sentiment and Short Positions
Market sentiment heading into the report has shown notable shifts. Short interest, representing bets against the stock, decreased significantly by 19.6% through mid-January, falling to roughly 1.9 million shares. This reduction suggests that some bearish investors have chosen to close their positions ahead of the quarterly announcement. Recent institutional activity has been mixed, with certain funds trimming their holdings while others added to their positions during the same timeframe.
Should investors sell immediately? Or is it worth buying Align?
The stock closed at $157.05 in Tuesday’s session. This price remains below the average analyst price target of $176.82. Whether the equity can bridge this gap will largely depend on the forward-looking guidance for the current fiscal year, which will accompany tonight’s earnings release.
Academic Partnership Strengthens Research Footprint
Separately, Align has confirmed its support for a major epidemiological study conducted by the University of Bern. The research aims to track oral health trends across Switzerland. This project will utilize Align’s iTero Lumina intraoral scanners. Data is scheduled to be collected from about 3,450 participants, including both children and adults, by the end of 2027. This initiative represents a deliberate integration of the company’s digital imaging technology into the academic research sphere.
Ad
Align Stock: Buy or Sell?! New Align Analysis from February 4 delivers the answer:
The latest Align figures speak for themselves: Urgent action needed for Align investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 4.
Align: Buy or sell? Read more here...
